Eli Lilly and Company’s next-generation GLP-1 receptor agonist is generating significant attention after delivering superior weight-loss results compared to Ozempic in a recent Phase II clinical trial. The investigational therapy builds on the growing success of GLP-1–based treatments, which mimic

Roche has announced the discontinuation of its late-stage Alzheimer’s clinical trial, SKYLINE, after an interim analysis revealed no meaningful cognitive benefit in patients. The decision marks a significant setback in the ongoing global effort to develop effective treatments for Alzheimer’s